Plain language summary of the EVOKE-01 study of sacituzumab govitecan vs docetaxel in patients with non-small cell lung cancer.
Plain language summary of the EVOKE-01 study of sacituzumab govitecan vs docetaxel in patients with non-small cell lung cancer. Future Oncol. 2025 May 15; 1-13.
PMID: 40371894
Adverse events self-reported by patients with extensive-stage small-cell lung cancer in the phase III CASPIAN study.
Adverse events self-reported by patients with extensive-stage small-cell lung cancer in the phase III CASPIAN study. Future Oncol. 2025 May; 21(12):1511-1523.
PMID: 40331625
Neoadjuvant versus perioperative chemo-immunotherapy according to pathological response in resectable NSCLC: a reconstructed individual patient data meta-analysis.
Neoadjuvant versus perioperative chemo-immunotherapy according to pathological response in resectable NSCLC: a reconstructed individual patient data meta-analysis. J Natl Cancer Inst. 2025 Apr 11.
PMID: 40210599
The Impact of the Tumor Microenvironment on the Effect of IL-1ß Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials.
The Impact of the Tumor Microenvironment on the Effect of IL-1ß Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials. Cancer Res Commun. 2025 Apr 01; 5(4):632-646.
PMID: 40116353
Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC With PD-L1 Expression of 50% or Higher: Five-Year Outcomes of EMPOWER-Lung 1.
Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC With PD-L1 Expression of 50% or Higher: Five-Year Outcomes of EMPOWER-Lung 1. J Thorac Oncol. 2025 Mar 19.
PMID: 40118215
Immunotherapy in advanced, KRAS G12C-mutant non-small-cell lung cancer: current strategies and future directions.
Immunotherapy in advanced, KRAS G12C-mutant non-small-cell lung cancer: current strategies and future directions. Ther Adv Med Oncol. 2025; 17:17588359251323985.
PMID: 40093982
The Role of GLP-1 Agonists in Mitigating Lorlatinib-Induced Metabolic Syndrome: Two Case Studies.
The Role of GLP-1 Agonists in Mitigating Lorlatinib-Induced Metabolic Syndrome: Two Case Studies. Clin Lung Cancer. 2025 Mar 04.
PMID: 40157899
Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.
Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature. 2025 Mar; 639(8054):E19.
PMID: 40016449
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1=50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry.
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1=50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry. J Immunother Cancer. 2025 Feb 04; 13(2).
PMID: 39904562
Osimertinib long-term tolerability in patients with EGFRm NSCLC enrolled in the AURA program or FLAURA study.
Osimertinib long-term tolerability in patients with EGFRm NSCLC enrolled in the AURA program or FLAURA study. Lung Cancer. 2025 Apr; 202:108417.
PMID: 40056874